Trial reportJournal of clinical hypertension (Greenwich, Conn.)2022
Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03541174 (Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)
Who cites it
16 citing papers in PubMed.
- Aprocitentan in Patients With Chronic Kidney Disease and Resistant Hypertension.Hypertension (Dallas, Tex. : 1979) · 2026Trial
- Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension.Journal of hypertension · 2026Trial
- Identifying and treating resistant hypertension in PRECISION: A randomized long-term clinical trial with aprocitentan.Journal of clinical hypertension (Greenwich, Conn.) · 2022Trial
- Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.American journal of preventive cardiology · 2026Article
- Review
- Factors associated with angiotensin II stimulating vs. inhibiting antihypertensive drug use in older adults.BMC geriatrics · 2026Article
- Regulatory Experiences with the Use of Multiple Imputation for Missing Data in a Phase 3 Confirmatory Trial.Therapeutic innovation & regulatory science · 2026Article
- Current Knowledge About Aprocitentan in Hypertension.International journal of molecular sciences · 2025Review
- Endothelin antagonists for hypertension: has their time finally arrived?Clinical science (London, England : 1979) · 2025Review
- Endothelin Receptor Antagonists for the Treatment of Hypertension: Recent Data from Clinical Trials and Implementation Approach.Current cardiology reports · 2025Review
- Resistant Hypertension: A Brief Review of Pathophysiology.Journal of general internal medicine · 2025Review
- Aprocitentan: First Approval.Drugs · 2024Review
- Hypertension and Heart Failure: From Pathophysiology to Treatment.International journal of molecular sciences · 2024Review
- Resistant Hypertension: Disease Burden and Emerging Treatment Options.Current hypertension reports · 2024Review
- Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs).Frontiers in pharmacology · 2024Review
- Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The design and baseline data of the PRECISION study, which evaluates the effect of the dual endothelin receptor antagonist aprocitentan on blood pressure (BP) in patients with resistant hypertension (RHT) are presented. The study is a blinded, randomized, parallel-group Phase 3 study and its three-part design assesses the short-term and sustained long-term effects of aprocitentan on BP. Results are expected in 2022. Patients with uncontrolled BP (measured as unattended automated office BP) despite the use of three or more antihypertensive medications for at least 1 year were screened. They were switched to a single-tablet triple fixed combination antihypertensive therapy for at least 4 weeks before entering a single-blind placebo run-in period. The 4-week placebo run-in period further excluded placebo responders. The randomization period consisted of three sequential parts: (1) a 4-week double-blind part with aprocitentan 12.5 mg, 25 mg, or placebo (1:1:1 ratio); (2) a 32-week single-blind part with aprocitentan 25 mg; and (3) a 12-week randomized withdrawal part with aprocitentan 25 mg or placebo (1:1 ratio). The purpose was to demonstrate the BP lowering effect of aprocitentan in RHT (Part 1) and the persistence of this effect (Parts 2 and 3). Out of 1965 screened patients, 730 were randomized resulting in an overall inclusion failure rate of 62.8%. The most common reason for exclusion (44.4% of all screened patients) was failure to meet the BP inclusion criteria. These results underline the high proportion of pseudoresistant hypertension among patients referred for RHT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.